The International Psoriasis Council proudly welcomes Alumis Inc. as a 2024 Bronze Level Corporate Member. Alumis is a clinical-stage biopharmaceutical company operating in the United States, focusing on improving patients’ lives with immune-mediated diseases by developing targeted therapies. Their goals to transform treatment and improve patient outcomes align with IPC’s mission to advance knowledge and improve care for those living with psoriasis.
“We are thrilled to welcome Alumis as a Corporate Member of IPC. Their commitment to developing therapies to transform the lives of patients with immune-mediated diseases, including psoriasis, will significantly strengthen IPC’s mission to advance psoriasis care worldwide,” said IPC CEO Christy Langan.
